Improving outcomes for patients with cardiogenic shock in Lower Silesia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Lower Silesia Cardiogenic Shock Initiative aims to enhance the treatment outcomes for patients experiencing cardiogenic shock in the Lower Silesia region of Poland. This project utilizes a Hub&Spoke model, with Wroclaw University Hospital serving as the central hub and eleven cardiology departments as spokes. A unified protocol has been established to determine which patients should be transferred to the hub for advanced treatment options, including mechanical circulatory support and heart transplants. The hub is staffed with a dedicated Shock Team available 24/7 to manage patient care and treatment decisions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Fulfilled definition of cardiogenic shock
2. Age 18 - 60 years
3. Shock duration below 24 hours

Exclusion Criteria:

1. History of cardiac arrest with anoxemic brain injury
2. Irreversible multiorgan failure
3. End stage of chronic diseases other than heart failure
4. Neoplastic disease
5. Lack of vascular access

Where it's running

• Institute of Heart Disease of Wroclaw Medical University
  Wroclaw, Poland Recruiting

Study contacts

• Study coordinator: Wiktor Kuliczkowski
• Email: wiktor.kuliczkowski@umed.wroc.pl
• Phone: +48717331112

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Factors Influencing Outcomes in ECMO and Impella Patients

  This study tests whether metabolic and thyroid hormone changes help predict survival for adults on ECMO or Impella at a single Hungarian cardiac ICU.

  Recruiting Gottsegen National Cardiovascular Institute · Budapest · NCT07885618

• Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients

  This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.

  Recruiting NIRSense Inc. · Weston, Florida · NCT07825363

• Safety and Efficacy of an Extracorporeal Ventricular Assist System for Cardiogenic Shock

  This study tests whether an extracorporeal ventricular assist device can safely provide short-term heart support and help patients with cardiogenic shock or trouble weaning from bypass.

  Recruiting China National Center for Cardiovascular Diseases · Beijing, Beijing Municipality · NCT07769528

• Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care

  In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.

  Recruiting Leipzig Heart Science gGmbH · Leipzig, Saxony · NCT07762560

• CRP Apheresis for infarct-related cardiogenic shock

  This study tests whether selectively removing C-reactive protein with apheresis, in addition to standard care, helps people with cardiogenic shock after a heart attack.

  Recruiting Leipzig Heart Science gGmbH · Leipzig, Saxony · NCT07687017

• Compare two ventilator modes in adults with cardiac ICU needs and invasive ventilation

  This pilot tests whether volume-controlled versus pressure-controlled ventilation can be safely used in adults with heart disease and respiratory failure who need invasive ventilation.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07656259

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.